FTC Sues Hims & Hers Over Data Sharing and Billing Practices
The FTC has filed suit against Hims & Hers, alleging improper health data sharing with Meta and Snap and deceptive billing practices.
Shares of Hims & Hers Health fell roughly 10% after the Federal Trade Commission filed a lawsuit against the telehealth company, targeting what regulators describe as troubling data-handling and consumer billing conduct. The action signals that the FTC remains willing to pursue high-profile digital health companies even amid shifting enforcement priorities in Washington.
At the heart of the complaint are allegations that Hims & Hers shared sensitive health information with technology giants Meta and Snap — platforms whose core business model revolves around advertising. When users trust a health platform with intimate medical details, the routing of that data toward social media advertising infrastructure raises serious questions about informed consent and the boundary between healthcare and commerce.
Read more Chipotle Raises Sales Forecast Amid Cyclospora Scare Impact →
Regulators also took aim at the company's billing practices and the ease — or lack thereof — with which subscribers can cancel their memberships. Subscription cancellation friction has become a recurring theme in FTC enforcement, reflecting the agency's broader concern that companies design checkout flows to capture revenue rather than serve customers. For a company operating in telehealth, where customers often face ongoing prescriptions and recurring charges, those dynamics carry added weight.
The lawsuit arrives at a consequential moment for the direct-to-consumer telehealth sector, which expanded rapidly during the pandemic and has faced mounting regulatory and market scrutiny since. Hims & Hers, which sells treatments for conditions ranging from hair loss to mental health, has positioned itself as a consumer-friendly alternative to traditional healthcare. The FTC's action challenges whether that positioning holds up under regulatory review.
The immediate market reaction — a double-digit share decline — underscores how acutely investors are pricing regulatory risk into digital health names. Whether the company will settle or contest the charges will shape the compliance landscape for the broader telehealth industry. Continue reading at US Top News and Analysis.
